Gabapentin Efficacy Study for Prurigo Nodularis Patient Outcomes

Supplementary material from a 12-week prospective monocentric observational study on prurigo nodularis treatment. The study involved 26 patients comparing gabapentin combined with antihistamines versus antihistamine monotherapy. The material was authored by Karger via figshare and last updated in April 2026.

Use Cases

• Compare treatment group outcomes using metrics like Peak Pruritus Numerical Rating Scale (PP-NRS) and Sleep Disturbance-NRS (SD-NRS) scores.
• Analyze the correlation between gabapentin dosage adjustments and Investigator's Global Assessment (IGA) scores over the 12-week period.
• Assess patient quality of life and mental health impact via Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression Scale (HADS) data.
• Evaluate the 'itching response' rate, defined as a PP-NRS reduction greater than 50% or 4 points from baseline, between combination and monotherapy groups.

Strengths

• Study reports on 26 patient records with detailed clinical assessments over a 12-week observation period.
• Outcomes are measured using 5 standardized clinical scales: PP-NRS, SD-NRS, DLQI, HADS, and IGA.
• Results include specific efficacy metrics, such as 75.0% itching response in the combination group versus 35.7% in the monotherapy group.

Limitations

• Very small sample size of 26 patients from a single center limits statistical power and generalizability.
• Dataset scope is limited to 18.6 KB of supplementary material, not the primary raw clinical data.
• Observational design without randomization introduces potential for confounding factors.

Provenance

Source

Karger (publisher), via figshare.

Collection Method

Prospective real-world observational study conducted at a single center.

Time Range

Study conducted over a 12-week period.

Freshness

Last updated in April 2026, indicating recent availability.

Geography

Monocentric study; specific geographic location is not provided.